Dyne Therapeutics (NASDAQ:DYN) Director Jason Rhodes Sells 287,956 Shares

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 287,956 shares of the company’s stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $19.68, for a total value of $5,666,974.08. Following the completion of the transaction, the director owned 11,663 shares in the company, valued at $229,527.84. This represents a 96.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Price Performance

Shares of NASDAQ:DYN traded up $0.46 on Wednesday, hitting $19.67. The company’s stock had a trading volume of 2,148,963 shares, compared to its average volume of 2,169,838. The company has a market capitalization of $3.25 billion, a PE ratio of -5.56 and a beta of 1.29. The company has a debt-to-equity ratio of 0.15, a current ratio of 22.25 and a quick ratio of 22.25. The company has a 50-day simple moving average of $17.52 and a 200 day simple moving average of $18.35. Dyne Therapeutics, Inc. has a 1 year low of $8.06 and a 1 year high of $25.00.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Monday, March 2nd. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.02). Sell-side analysts forecast that Dyne Therapeutics, Inc. will post -2.94 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. HC Wainwright cut their price target on shares of Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, March 3rd. Jefferies Financial Group reaffirmed a “buy” rating on shares of Dyne Therapeutics in a research note on Monday, March 9th. Morgan Stanley cut their price objective on Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating on the stock in a research report on Monday, March 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Monday. Finally, Wall Street Zen downgraded Dyne Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, December 28th. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Dyne Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $35.14.

Institutional Investors Weigh In On Dyne Therapeutics

A number of hedge funds have recently added to or reduced their stakes in DYN. Pictet Asset Management Holding SA increased its position in Dyne Therapeutics by 49.4% during the first quarter. Pictet Asset Management Holding SA now owns 19,372 shares of the company’s stock valued at $351,000 after acquiring an additional 6,409 shares during the last quarter. Wasatch Advisors LP lifted its holdings in Dyne Therapeutics by 9.0% during the first quarter. Wasatch Advisors LP now owns 443,668 shares of the company’s stock valued at $8,044,000 after purchasing an additional 36,708 shares in the last quarter. Hilton Head Capital Partners LLC bought a new position in Dyne Therapeutics in the 1st quarter worth $26,000. Rockefeller Capital Management L.P. grew its position in shares of Dyne Therapeutics by 67.1% during the fourth quarter. Rockefeller Capital Management L.P. now owns 14,268 shares of the company’s stock worth $279,000 after purchasing an additional 5,730 shares in the last quarter. Finally, Seven Fleet Capital Management LP purchased a new stake in Dyne Therapeutics during the 4th quarter valued at approximately $1,373,000. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.